Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial

Kiyota, Naomi; Tahara, Makoto; Mizusawa, Junki; Kodaira, Takeshi; Fujii, Hirofumi; Yamazaki, Tomoko; Mitani, Hiroki; Iwae, Shigemichi; Fujimoto, Yasushi; Onozawa, Yusuke; Hanai, Nobuhiro; Ogawa, Takenori; Hara, Hiroki; Monden, Nobuya; Shimura, Eiji; MINAMI, SHUJIRO; Fujii, Takashi; Tanaka, Kaoru; Homma, Akihiro; Yoshimoto, Seiichi; Oridate, Nobuhiko; Omori, Koichi; Ueda, Tsutomu; Okami, Kenji; Ota, Ichiro; Shiga, Kiyoto; Sugasawa, Masashi; Asakage, Takahiro; Saito, Yuki; Murono, Shigeyuki; Nishimura, Yasumasa; Nakamura, Kenichi; Rh, Hayashi

doi:10.1200/jco.21.01293

Public

Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial

Published in Journal of Clinical Oncology • Mar 1, 2022

Authors:

Naomi Kiyota

Makoto Tahara

Junki Mizusawa

Abstract

PURPOSE The standard treatment for postoperative high-risk locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) is chemoradiotherapy with 3-weekly cisplatin (100 mg/m 2 ). However, whether chemoradiotherapy with weekly cisplatin (40 mg/m 2 ) yields comparable efficacy with 3-week...

Subject

Medicine

Cisplatin

Head and neck cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!